Biotech company Revvity Inc. (RVTY) is expected to reveal an increase in earnings and has announced a $0.07 per share quarterly dividend by May 2025. The company has seen a 30% return over the last five years, and analysts forecast promising prospects for the firm. In its next earnings report, RVTY is expected to outdo predictions once again. The stock shares saw a 3.21% increase on January 21st, with SG Americas Securities LLC boasting $4.53 million in holdings. Despite this, Leerink Partnrs anticipates a negative outlook for Q4 earnings and the stock has dropped 8.7% since the last earnings report. Revvity continues to innovate within the bio-tech sector and announced its partnership with Element Biosciences to improve neonatal genetic testing. Notably, it also achieved FDA clearance for the first-ever automated free testosterone test. However, RVTY has downgraded their 2024 revenue amid a slowdown in biotech spending, but they expect to beat the 2024 EPS guidance due to strong Q4 revenue growth.
Revvity RVTY News Analytics from Tue, 09 May 2023 07:00:00 GMT to Sat, 25 Jan 2025 13:57:03 GMT - Rating 5 - Innovation 4 - Information 8 - Rumor -3
